Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s CHMP has blessed Etcamah with a positive opinion. The EMA also has signed off on Novo Nordisk's Wegovy pill.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
EU and US advisers split over AstraZeneca breast cancer drug
AstraZeneca picks up FDA approval for hypertension drug
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
AstraZeneca's blood pressure pill approved, but competition could be around the corner
New data show VEGF bispecifics could compete with Summit, Akeso drug
Europe's CHMP backed AstraZeneca's camizestrant for breast cancer, diverging from a recent FDA committee vote, as well as Novo…
Enhertu’s market conquest is continuing apace. | Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA…
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in…
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…
